Developing immunobiological products for healthy and safe future
CJSC "RBT" — the developer of own "Betusphere" platform for development of combined adjuvant systems for vaccines with a high safety profile
team members
20+
completed biotech projects
29+
years on the vaccine market
11+
years of experience in R&D of biotech products
40+
The "BetuSphere" platform offers extensive opportunities for the portfolio development and creation of new vaccines
COVID-19 vaccine
"BetuVax"
Co-development
Product
Phase
Influenza vaccine
"TetraFluBet"
Immunimodulator
"BetuSphere"
Against human papillomavirus
HPV vaccine
Against influenza and COVID-19
Combination vaccine
"UltrixCombi"
"UltrixCombi"
Co-development
Fast-track
registration
procedure
registration
procedure
Fast-track
registration
procedure
registration
procedure
Phase II−III
Phase II
Pre-clinical
About
The "RBT" company was established in 2011 for R&D projects in the field of innovative medicines. By combining research experience with successful practical implementation, "RBT" develops challenging projects in the area of biopharmaceuticals.
In 2021, "Artgen Biotech" invested in the development of "RBT" biotechnology platform and creation a number of vaccine drugs against infectious diseases.
In June 2022, the company was assigned the status of a participant in the project for the creation and maintenance of the Skolkovo Innovation Center.
In 2021, "Artgen Biotech" invested in the development of "RBT" biotechnology platform and creation a number of vaccine drugs against infectious diseases.
In June 2022, the company was assigned the status of a participant in the project for the creation and maintenance of the Skolkovo Innovation Center.
Welcome our team with the successful experience in launching vaccines on the market, attracting investments and biotech IPOs.
- Igor KrasilnikovCEOPh.D, Dr.Sci, Prof., International WHO advisor in vaccine development (Initiative for Vaccine Research program)
- Artur IsaevStrategist, anchor investorFounder of "Artgen Biotech", "Gemabank" — the largest russian bank of umbilical cord blood stem cells
- Mark KolotovCDOex-GSK (UK) Regional Director of Vaccine Department, ex-Boehringer Ingelheim (Germany) Regional Manager, ex-Aventis Pasteur (France) Key Account Manager
- Taras Ivanishin
COO
5+ years of experience in biotech investments. Lomonosov MSU Faculty of Chemistry, Russian Presidential Academy of National Economy and Public Administration - Pavel PogodinDirector of Legal Affairs10+ years of experience in management positions in the state and biotech sector
- Irina TcymbarevichCTOPhD, UZH (imMed), 7+ years of experience in pharmaceutical R&D and technology development
- Denis ShanyginIR Managerex-Biomark Capital USA Project Manager (Russian Branch)
- Maria FrolovaScientific AdvisorPhD, Heidelberg University
- Milana DjonovicSenior R&D ConsultantExperience in gene therapy drug development, patenting, bioinformatics
Contacts
CJSC (Closed Joint-Stock Company)
"Biotechnology Developments"
(CJSC RBT)
TIN: 9729341365
RRC: 772901001
PSRN: 1237700160070
Address: 96, pr-kt Vernadskogo "Moscow Center for Healthcare and Innovations"
"Biotechnology Developments"
(CJSC RBT)
TIN: 9729341365
RRC: 772901001
PSRN: 1237700160070
Address: 96, pr-kt Vernadskogo "Moscow Center for Healthcare and Innovations"
Phone: +7(993)357-99-03
E-mail: info@rbiotech.ru
E-mail: info@rbiotech.ru
By pressing button you confirm your consent to the processing of your personal data and the Confidentiality Policy
Research is carried out with the grant support of the Skolkovo Foundation.
© "Biotechnology Developments", 2023